REFERENCES
- Salitl E, Sano M, Boggild AK, Kain KC. Travel patterns and risk behaviour of HIV-positive people travelling internation-ally. CMAJ. 2005;172:884–888.
- Sherrard AW, McCarthy AE. Travel patterns and health risks for patients infected with HIV. Travel Med Infect Dis. 2009;7:291–295.
- Centers for Disease Control and Prevention. CDC Health. Information for International Travel 2012: The Yellow Book. Chapter 3: Infectious diseases related to travel. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infec-tious-diseases-related-to-travel/malaria.htm
- Khoo S, Back D, Winstanley P. The potential for interac-tions between antimalarial and antiretroviral drugs. AIDS. 2005;19:995–1005.
- Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr. 2004;36:649–658.
- George AM, Dvey MW, Mir AA. Functional expression of the human MDR1 gene in Escherichia coli. Arch Biochem Biophys. 1996;333: 66–74.
- Washington CB, Wiltshire HR, Man M, et al. The disposi-tion of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos. 2000;28:1058–1062.
- Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet. 2002;359:30–36.
- Almond LM, Edirisinghe D, Dalton M, Bomington A, Back DJ, Khoo SH. Intracellular and plasma pharma-cokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther. 2005;78: 132–142.
- Abgrall S, Fugon L, Lélé N, et al. Visiting one’s native country: The risks of nonadherence in HIV-infected sub-Saharan migrants - ANRS VIHVO Study [published online ahead of print May 22,2013]. J Int Assoc Provid. AIDS Care.
- Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007;21:1095–1104.
- Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657–680.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Rockville, MD: Author; January 31,2001.
- Zhou J, He Y, Yuan Y. Comparison of Schuirmann’s Two One-Sided Tests with non nonparametric Two One-Sided Tests for non-normal data in clinical pharmacoki-netic drug-drug interaction studies. Online J Pharmacol Pharmacokinet. 2004;2:33–43.
- Panhard X, Mentre F. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacoki-netic interaction and bioequivalence cross-over trials. Stat Med. 2005;24:1509–1524.
- Brentlinger PA, Behrens CB, Kublin JG. Challenges in the prevention, diagnosis, and treatment of malaria in human-immunodeficiency virus-infected adults in sub-Saharan Africa. Arch Intern Med. 2007;167:1827–1836.
- Mouala C, Guiguet M, Houzé S, et al; FHDH-ANRS co4 Clinical Epidemiology Group. Impact of HIV infec-tion on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. AIDS. 2009:23;1997–2004.